Interactive Home-based Rehabilitation Exercise Assessment Platform and Exploration of Clinical Effects in Patients with Parkinson's Disease (PD)

The Development and Verification of an Interactive Home-based Rehabilitation Exercise Assessment Platform and Exploration of Technology Acceptance and Clinical Effects in Patients with Parkinson's Disease

This study aims to develop an "Interactive Home-based Rehabilitation Exercise Assessment Platform" that incorporates visual feedback similar to virtual reality into rehabilitation machines and aerobic cycling programs. In the clinical research part, 92 Parkinson's disease patients will be randomly assigned to three groups: the clinical rehabilitation group, the home-based rehabilitation group, and the control group. Each group will undergo the intervention twice a week, with each session lasting about 30-45 minutes over a period of 12 weeks for a total of 24 combined resistance and aerobic rehabilitation training sessions. The effectiveness evaluation will include measurements of upper limb grip strength, lower limb muscle strength, the 3-meter sit-to-stand test, the 6-minute walk test, the Parkinson's Disease Severity Scale, the Quality of Life Scale, the 10-meter walk test, and technology acceptance forms.

Study Overview

• Status: Not yet recruiting
• Conditions: Parkinson Disease
• Intervention / Treatment: Other: Other: Clinical rehabilitation group; Other: Other: Home-based rehabilitation group

Detailed Description

Background and Purpose: Previous research on technological interventions in exercise therapy for Parkinson's disease has shown that incorporating visual feedback through virtual reality into rehabilitation exercise programs can improve patients' balance, muscle strength, gait, and other functional performances. This study aims to develop an "Interactive Home-based Rehabilitation Exercise Assessment Platform" that incorporates visual feedback similar to virtual reality into rehabilitation machines and aerobic cycling programs. The platform uses sensors and interactive games to guide correct rehabilitation movements. The effectiveness of the platform will be validated through engineering-related tests and clinical trials further to investigate its clinical benefits for Parkinson's disease patients.

Methods: This study consists of two parts: platform development and validation and clinical research. The platform will be implemented for use in medical institutions and at home, specifically at Taipei Veterans General Hospital, utilizing six rehabilitation machines and aerobic bicycles, as well as home-based cycling combined with resistance band training. Interactive game software and laser sensors will be developed. Sensors will collect patients' physiological parameters during the rehabilitation process to ensure safety and provide real-time feedback on movements and time control during the sessions. The collected data, including angle values, cycling revolutions, and physiological parameters, will be verified for usability using commercially available products.

In the clinical research part, 92 Parkinson's disease patients will be randomly assigned to three groups: the clinical rehabilitation group, the home-based rehabilitation group, and the control group. Each group will undergo the intervention twice a week, with each session lasting about 30-45 minutes over a period of 12 weeks for a total of 24 combined resistance and aerobic rehabilitation training sessions. The effectiveness evaluation will include measurements of upper limb grip strength, lower limb muscle strength, the 3-meter sit-to-stand test, the 6-minute walk test, the Parkinson's Disease Severity Scale, the Quality of Life Scale, the 10-meter walk test, and technology acceptance forms. Statistical analysis will be performed using one-way ANOVA and chi-square tests to analyze personal data characteristics. For clinical effectiveness analysis, a two-way (group by time) ANOVA with repeated measures will be used to examine differences between groups and over time, with Bonferroni tests for post-hoc comparisons. All data will be analyzed using SPSS version 24, with a p-value of less than 0.05, which is considered statistically significant.

• Study Type: Interventional
• Enrollment (Estimated): 92
• Phase: Not Applicable

Contacts and Locations

• Study Contact: Name: CHEN WEI-DI PhD candidate; Phone Number: 886-966070329; Email: wdchen.be11@nycu.edu.tw

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

1. Patients diagnosed with primary Parkinson's disease by a neurologist
2. Modified Hoehn and Yahr Scale I-III
3. Aged 45-85 years old
4. Mini-Mental State Examination (MMSE) score of 24 or above
5. Stable on Parkinson's disease-related medications
6. Able to walk independently or use assistive devices to walk 15 meters
7. Able to understand the movements and test items
8. Able to understand and willing to sign the informed consent form

Exclusion Criteria:

1. Rheumatic diseases
2. Unstable heart and respiratory diseases (such as angina pectoris, pulmonary embolism, etc.)
3. Severe or unstable neurological or orthopedic diseases (such as stroke, dementia, fractures, etc.)
4. Severe hearing or visual impairment, unable to cooperate with researchers
5. People diagnosed with mental illness
6. People with a history of epilepsy or a direct blood relative with a history of epilepsy
7. Pregnant or breastfeeding women
8. People with any uncontrolled chronic diseases that may cause safety concerns
9. People living without family members or case caregivers.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Single

Number of Arms

3

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Experimental: Clinical rehabilitation; Participants in this group would be treated with exercise rehabilitation for twice a week, total 12 weeks in the hospitals.	Other: Other: Clinical rehabilitation group; Rehabilitation training for twice a week, total 12 weeks in hospitals.
Active Comparator: Active Comparator: Home-based rehabilitation; Rehabilitation training for twice a week, total 12 weeks at home.	Other: Other: Home-based rehabilitation group; Rehabilitation training for twice a week, total 12 weeks at home.
No Intervention: No Intervention: Control; The control group received Parkinson's disease treatment-related medication and was asked to maintain daily activities according to their usual lifestyle.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change from Baseline Timed Up and Go test (TUG) at 12 weeks	The time score is lower, means the gait function is better.	pre-test(first time) and post-test(after 12 weeks)
Change from Baseline muscle strength of upper limbs at 12 weeks	The muscle strength of upper limbs score is higher, means the upper limbs is better.	pre-test(first time) and post-test(after 12 weeks)
Change from Baseline muscle strength of lower limbs at 12 weeks	The muscle strength of lower limbs score is higher, means the upper limbs is better.	pre-test(first time) and post-test(after 12 weeks)
Change from Baseline gait Speed at 12 weeks	The gait Speed time score is lower, means the gait function is better.	pre-test(first time) and post-test(after 12 weeks)
Change from Baseline the Mini-Mental State Exam (MMSE) at 12 weeks	The Mini-Mental State Exam score is higher, means the Cognitive function is better.	pre-test(first time) and post-test(after 12 weeks)
Change from Baseline Quality of Life Scale(PDQ39) at 12 weeks	Quality of Life Scale score is higher, means the Quality of Life is better.	pre-test(first time) and post-test(after 12 weeks)
Change from Baseline technology acceptance forms at 12 weeks	Technology acceptance forms score is higher, means theTechnology acceptance is better.	pre-test(first time) and post-test(after 12 weeks)
Change from Baseline The unified Parkinson's disease rating scale(UPDRS) at 12 weeks	The unified Parkinson's disease rating scale(UPDRS) score is lower, means Disease severity is better.	pre-test(first time) and post-test(after 12 weeks)
Change from Baseline IPAQ Taiwan Activity Survey at 12 weeks	No score in this IPAQ Taiwan Activity Survey form.	pre-test(first time) and post-test(after 12 weeks)
Change from Baseline Six-minute walk distance at 12 weeks	The Six-minute walk distance time score is lower, means walk distance is better.	pre-test(first time) and post-test(after 12 weeks)

Collaborators and Investigators

• Sponsor: Taipei Veterans General Hospital, Taiwan
• Collaborators: Far Eastern Memorial Hospital

Study record dates

Study Major Dates

• Study Start (Estimated): March 21, 2025
• Primary Completion (Estimated): December 31, 2025
• Study Completion (Estimated): January 31, 2026

Study Registration Dates

• First Submitted: March 17, 2025
• First Submitted That Met QC Criteria: March 17, 2025
• First Posted (Actual): March 25, 2025

Study Record Updates

• Last Update Posted (Estimated): March 26, 2025
• Last Update Submitted That Met QC Criteria: March 21, 2025
• Last Verified: March 1, 2025

More Information

Terms related to this study

• Keywords: Parkinson; visual feedback; Exercise intervention
• Additional Relevant MeSH Terms: Synucleinopathies; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Neurodegenerative Diseases; Movement Disorders; Parkinsonian Disorders; Basal Ganglia Diseases; Parkinson Disease
• Other Study ID Numbers: 2024-12-004A

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No